Skip to content
The Policy VaultThe Policy Vault

imatinib mesylate — CareFirst (Caremark)

Chronic Eosinophilic Leukemia (CEL)

Initial criteria

  • Diagnosis of HES or CEL

Reauthorization criteria

  • No evidence of unacceptable toxicity or disease progression while on current regimen

Approval duration

12 months